51
|
Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, De Belder MA, Kwok CS, Rashid M, Fischman DL, Mamas MA. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2018; 40:1790-1800. [DOI: 10.1093/eurheartj/ehy769] [Citation(s) in RCA: 84] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Revised: 07/25/2018] [Accepted: 11/16/2018] [Indexed: 12/17/2022] Open
Affiliation(s)
- Jessica E Potts
- Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Keele Road, Stoke-on-Trent, UK
| | - Cezar A Iliescu
- Department of Cardiology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - Juan C Lopez Mattei
- Department of Cardiology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
| | - Sara C Martinez
- Division of Cardiology, Providence St. Peter Hospital, Olympia, WA, USA
| | - Lene Holmvang
- Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Peter Ludman
- Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - Mark A De Belder
- Department of Cardiology, James Cook University Hospital, Middlesborough, UK
| | - Chun Shing Kwok
- Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Keele Road, Stoke-on-Trent, UK
- Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, UK
| | - Muhammad Rashid
- Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Keele Road, Stoke-on-Trent, UK
- Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, UK
| | - David L Fischman
- Department of Medicine (Cardiology), Thomas Jefferson University Hospital, Philadelphia, PA, USA
| | - Mamas A Mamas
- Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Keele Road, Stoke-on-Trent, UK
- Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, UK
| |
Collapse
|
52
|
Abstract
Cardiologists are seeing an increasing number of oncology patients every day, and acute coronary syndrome (ACS) is one of the problems patients encounter during follow-up. Cardio-oncology is the care of patients with cancer and cardiovascular disease, whether overt or occult, already established or acquired during treatment. Cardiovascular complications can occur acutely during or shortly after treatment and persist as long-term effects for months to years after treatment. As a delayed effect of cancer treatment, cardiovascular damage can occur months to years after the initial treatment. Vasospasm, thrombosis, and radiation-induced cardiovascular diseases can all cause ACS. Careful surveillance of ACS symptoms and regular screening during follow-up of patients with malignancy are suggested. In this review, we summarize the ACS we usually encounter during a range of cancer treatments or post cancer survival by providing illustrative case examples.
Collapse
Affiliation(s)
- Begum Yetis Sayin
- Department of Cardiology, Memorial Ankara Hospital, Mevlana Boulevard number 4, Balgat, Ankara, Turkey.
| | - Mehmet Ali Oto
- Department of Cardiology, Memorial Ankara Hospital, Mevlana Boulevard number 4, Balgat, Ankara, Turkey
| |
Collapse
|
53
|
Gong IY, Yan AT, Ko DT, Earle CC, Cheung WY, Peacock S, Hall M, Gale CP, Chan KKW. Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. Cancer 2018; 124:1269-1278. [PMID: 29211307 PMCID: PMC7614832 DOI: 10.1002/cncr.31174] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2017] [Revised: 11/01/2017] [Accepted: 11/03/2017] [Indexed: 11/11/2022]
Abstract
BACKGROUND There is a paucity of information about treatment and mortality trends after acute myocardial infarction (AMI) for cancer survivors (CS). METHODS In this population-based study, the authors compared temporal trends of treatments and outcomes (mortality, nonfatal cardiovascular outcomes), among CS and patients without cancer (the noncancer patient [NCP] group) with AMI in Ontario (Canada) using inverse probability treatment weight (IPTW)-adjusted modeling. RESULTS Of 270,089 patients with AMI (22,907 CS, 247,182 NCP, 1995-2013; median follow-up, 10.1 and 11.0 years, respectively), the use of invasive coronary strategies and pharmacotherapies increased and mortality declined for CS and NCP (all Ptrend < .001). At 30 days after AMI, there was no difference between CS and NCP in the receipt of coronary angiography (incidence risk ratio [IRR], 0.98; 95% confidence interval [CI], 0.96-1.01; P = .23), percutaneous coronary intervention (IRR, 0.98; 95% CI, 0.94-1.02; P = .29), or bypass (IRR, 0.93; 95% CI, 0.85-1.02; P = .11). At 90 days after AMI, there was no difference in the receipt of β-blockers, clopidogrel, or nitrates; but CS were less often prescribed angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and statins. CS had higher all-cause mortality at 30 days (adjusted hazard ratio [HR] 1.12; 95% CI, 1.07-1.17; P < .001), at 1 year (1.16; 95% CI, 1.12-1.20; P < .001), and long term (HR, 1.21; 95% CI, 1.17-1.25; P < .001) and had a greater risk of heart failure (HR, 1.08; 95% CI, 1.03-1.14; P = .001), but not myocardial re-infarction (HR, 0.98; 95% CI, 0.95-1.01; P = .22) or stroke (HR, 1.06; 95% CI, 0.97-1.16; P = .18). CONCLUSIONS Among CS and NCP with AMI in Ontario, similar improvements in mortality and receipt of treatments were observed between 1995 and 2013. However, compared with NCP, CS had a higher risk of mortality and heart failure. Cancer 2018;124:1269-78. © 2017 American Cancer Society.
Collapse
Affiliation(s)
- Inna Y Gong
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Andrew T Yan
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada
| | - Dennis T Ko
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
- Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
| | - Craig C Earle
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
- Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Winson Y Cheung
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Stuart Peacock
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- Canadian Center for Applied Research in Cancer Control, Ontario and British Columbia, Canada
| | - Marlous Hall
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom
| | - Chris P Gale
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom
| | - Kelvin K W Chan
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
- Canadian Center for Applied Research in Cancer Control, Ontario and British Columbia, Canada
| |
Collapse
|
54
|
Giza DE, Marmagkiolis K, Mouhayar E, Durand JB, Iliescu C. Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective. Curr Cardiol Rep 2017; 19:56. [PMID: 28484995 DOI: 10.1007/s11886-017-0862-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
PURPOSE OF REVIEW Coronary artery disease in patients with active cancer presents particular challenges for clinicians, as optimum management is required in order to treat the underlying malignancy and to reduce morbidity and mortality associated with cardiovascular diseases. Special considerations must be made in respect to either primary or secondary thrombocytopenia, the presence of coagulopathies and the propensity of bleeding, vascular access complications, and increased risk of stent thrombosis. RECENT FINDINGS In presence of acute coronary symptoms, the cardio-oncology team has to make a complex decision between conservative medical management or early angiography (within 24 h) and revascularization. There is a lack of reliable data on the outcomes of patients with active cancer who undergo invasive procedures for the diagnostic and treatment of coronary artery disease. Cardiac catheterization recommendations in cancer patients are being currently elaborated by cardio-oncologists in order to improve the overall survival in cancer patients with coronary artery disease.
Collapse
Affiliation(s)
- Dana Elena Giza
- Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
| | - Kostas Marmagkiolis
- Department of Cardiology, University of Missouri, Columbia, 1500 N Oakland Ave, Bolivar, MO, 65613, USA
| | - Elie Mouhayar
- Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
| | - Jean-Bernard Durand
- Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
| | - Cezar Iliescu
- Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.
| |
Collapse
|
55
|
|
56
|
Öner A, Ince H, Paranskaya L, Schröder G, Sherif M, Thiele O, Neuhausen A, Kische S, Ortak J, D′Ancona G. Previous malignancy is an independent predictor of follow-up mortality after percutaneous treatment of mitral valve regurgitation by means of MitraClip. Cardiovasc Ther 2017; 35. [DOI: 10.1111/1755-5922.12239] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Revised: 11/21/2016] [Accepted: 12/01/2016] [Indexed: 11/28/2022] Open
Affiliation(s)
- Alper Öner
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Hüseyin Ince
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Liliya Paranskaya
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Guido Schröder
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Mohammad Sherif
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Olga Thiele
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Alla Neuhausen
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Stephan Kische
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Jasmin Ortak
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| | - Giuseppe D′Ancona
- Heart Center Rostock; Rostock School of Medicine; University Hospital Rostock; Rostock Germany
- Department of Cardiology; Vivantes Klinikum im Friedrichshain und Am Urban; Berlin Germany
| |
Collapse
|
57
|
Landes U, Kornowski R, Bental T, Assali A, Vaknin-Assa H, Lev E, Iakobishvili Z. Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis 2017; 28:5-10. [DOI: 10.1097/mca.0000000000000429] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
58
|
Wang F, Gulati R, Lennon RJ, Lewis BR, Park J, Sandhu GS, Wright RS, Lerman A, Herrmann J. Cancer History Portends Worse Acute and Long-term Noncardiac (but Not Cardiac) Mortality After Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Mayo Clin Proc 2016; 91:1680-1692. [PMID: 27916154 DOI: 10.1016/j.mayocp.2016.06.029] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 06/24/2016] [Accepted: 06/27/2016] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To define the effect of a history of cancer on in-hospital and long-term mortality after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). PATIENTS AND METHODS In this retrospective cohort study of 2346 patients with STEMI enrolled in the Mayo Clinic PCI registry from November 1, 2000, through October 31, 2010, we identified 261 patients (11.1%) with a history of cancer. The in-hospital and long-term outcomes (median follow-up, 6.2 years; interquartile range=4.3-8.5 years), including cardiac and noncardiac death and heart failure hospitalization, of these patients were compared with those of 1313 cancer-negative patients matched on age, sex, family history of coronary artery disease, and date of STEMI. RESULTS Patients with cancer had higher in-hospital noncardiac (1.9% vs 0.4%; P=.03) but similar cardiac (5.8% vs 4.6%; P=.37) mortality as matched controls. The group at highest acute mortality risk were those diagnosed as having cancer within 6 months before STEMI (hazard ratio [HR]=7.0; 95% CI, 1.4-34.4; P=.02). At 5 years, patients with cancer had similar cardiac mortality (4.2% vs 5.8%; HR=1.27; 95% CI, 0.77-2.10; P=.35) despite more heart failure hospitalizations (15% vs 10%; HR=1.72; 95% CI, 1.18-2.50; P=.01) but faced higher noncardiac mortality (30.0% vs 11.0%; HR=3.01; 95% CI, 2.33-3.88; P<.001) than controls, attributable solely to cancer-related deaths. CONCLUSION One in 10 patients in this contemporary registry of patients undergoing primary PCI for STEMI has a history of cancer. These patients have more than a 3 times higher acute in-hospital and long-term noncardiac mortality risk but no increased acute or long-term cardiac mortality risk with guideline-recommended cardiac care.
Collapse
Affiliation(s)
- Feilong Wang
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
| | - Rajiv Gulati
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
| | - Ryan J Lennon
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN
| | - Bradley R Lewis
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN
| | - Jae Park
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
| | | | - R Scott Wright
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
| | - Amir Lerman
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN
| | - Joerg Herrmann
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
| |
Collapse
|